These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19356110)

  • 1. Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class.
    Qiu Q; Larroque AL; Gibbs B; Fang Y; Lakhrissi Y; Soucy JP; Mzengeza S; Rachid Z; Jean-Claude BJ
    Drug Metab Lett; 2009 Jan; 3(1):1-9. PubMed ID: 19356110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule.
    Golabi N; Rachid Z; Qiu Q; Huang Y; Jean-Claude BJ
    Drug Metab Lett; 2011 Apr; 5(2):141-9. PubMed ID: 21457144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
    J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo.
    Merayo N; Rachid Z; Qiu Q; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2006 Feb; 17(2):165-71. PubMed ID: 16428934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
    Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
    Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
    Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.
    MacPhee M; Rachid Z; Todorova M; Qiu Q; Belinsky G; Jean-Claude BJ
    Invest New Drugs; 2011 Oct; 29(5):833-45. PubMed ID: 20428924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept.
    Banerjee R; Rachid Z; McNamee J; Jean-Claude BJ
    J Med Chem; 2003 Dec; 46(25):5546-51. PubMed ID: 14640561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species.
    Todorova MI; Larroque AL; Dauphin-Pierre S; Fang YQ; Jean-Claude BJ
    Mol Cancer Ther; 2010 Apr; 9(4):869-82. PubMed ID: 20354119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
    Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B
    Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3- (methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity.
    Rouzer CA; Sabourin M; Skinner TL; Thompson EJ; Wood TO; Chmurny GN; Klose JR; Roman JM; Smith RH; Michejda CJ
    Chem Res Toxicol; 1996; 9(1):172-8. PubMed ID: 8924588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
    Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
    Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triazene compounds: mechanism of action and related DNA repair systems.
    Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
    Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
    Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
    Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
    Matheson SL; Brahimi F; Jean-Claude BJ
    Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes.
    Carvalho E; Francisco AP; Iley J; Rosa E
    Bioorg Med Chem; 2000 Jul; 8(7):1719-25. PubMed ID: 10976519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24.
    Banerjee R; Huang Y; McNamee JP; Todorova M; Jean-Claude BJ
    J Pharmacol Exp Ther; 2010 Jul; 334(1):9-20. PubMed ID: 20348204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, and antitumor properties.
    Vaughan K; Tang Y; Llanos G; Horton JK; Simmonds RJ; Hickman JA; Stevens MF
    J Med Chem; 1984 Mar; 27(3):357-63. PubMed ID: 6699881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism of triazene antitumor drugs.
    Gescher A; Threadgill MD
    Pharmacol Ther; 1987; 32(2):191-205. PubMed ID: 3299401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.